Subscribe to Search results

The New England Journal of Medicine stated: "If the use of cryoprecipitate will minimize this risk, the current home-infusion program needs to be revised".

Published on:

AIDS was discussed at the UK Haemophilia Centre Directors Hepatitis Working Party meeting.

Published on:

A meeting at Heathrow between haemophilia doctors and Immuno took place.

Published on:

The Lancet reported that a blood borne agent seemed the likely cause of AIDS.

Published on:

The New Scientist suggested "prime suspect" for the causation of AIDs was a blood borne virus.

Published on:

ln a letter to Professor Arthur Bloom, Dr Bruce Evatt (CDC) said that the AIDS epidemic was evolving with a frightening pace.

Published on:

Professor Bloom reported a probable case of AIDS to CDSC.

Published on:

An article in The Mail on Sunday described risk of AIDS.

Published on:

Professor Bloom's letter regarding AIDS was published by the Haemophilia Society.

Published on:

In his paper entitled "Action on AIDS", Dr Spence Galbraith, director of the CDSC, recommended the Department of Health and Social Security suspending importation of US blood products.

Published on:

A viral particle (then called "LAV") isolated in Paris by Dr Luc Montagnier turned out be the same as HTLV-3 and HIV.

Published on:

First death from AIDS in the UK of a person with haemophilia.

Published on:

The British Medical Journal commented that there was no evidence that any factor product was free from the risk of transmitting AIDS.

Published on:

Dr Robert Gallo announced he had found the virus which caused AIDS.

Published on:

An article in The Observer described the risk of AIDS.

Published on:

Article in The Observer described risk of AIDS.

Published on:

A report of a study at the Lord Mayor Treloar College concluded that "As antibody is evidence of previous exposure to serum hepatitis, it probably also indicates immunity and it is not surprising that clinical hepatitis is uncommon in adult haemophiliacs".

Published on:

It was stated that Treloar's was the only establishment in the United Kingdom which could provide the opportunity and the facilities for extensive clinical trials of various kinds of treatment and that this type of research could not be conducted anywhere else.

Published on:

It was noted that a proposed tranexamic acid trial at Treloar's would have to be arranged so that it did not "interfere with any future trial of prophylactic therapy".

Published on:

It was noted at Treloars that "an attempt would be made to trace the source of infection in every instance of hepatitis however mild clinically."

Published on: